A Biogen drug designed for a genetically defined form of amyotrophic lateral sclerosis led to patient improvement at a 12-month analysis, according to data now published in the New England Journal of Medicine. Biogen had already filed an application seeking FDA approval of the ALS drug, tofersen; a regulatory decision is expected by January.
In an alert on Friday, the Food and Drug Administration warmed that pulse oximeters might be inaccurate in some circumstances. The agency listed skin color among other factors that may affect the accuracy of a reading, but didn’t mention research that has demonstrated the devices miss low blood oxygen levels more often in Black patients.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
A randomized, placebo-controlled trial published in NEJM found the malaria drug was not effective as a post-exposure prophylaxis against coronavirus disease. However, questions have arisen about data used in a large observational study about the drug published last month.
The authors wrote that the data highlight the need to identify and start Covid-19 patients on antiviral therapy before they progress to requiring mechanical ventilation. The data were published in The New England Journal of Medicine.
Also, critics are questioning the credibility and direction of the New England Journal of Medicine, and Banner Health has reported that its operating income fell more than 50 percent.
Also, the Elizabethkingia outbreak in Wisconsin spreads, Valeant settles with R&O, while Austin, Texas, becomes a biotech hub.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The International Committee of Medical Journal Editors is proposing an official requirement that researchers submit data from clinical trials for any studies that will be published.
Now that there is a system of EHRs in place, smartphones are widespread and consumer demand for access to their health records is growing, it may be easier to achieve the data liquidity that eluded previous PHR purveyors.
Instead of just building apps that people may or may not use, healthcare innovators have started taking lessons from counterparts in other industries by testing their ideas first, according to University of Pennsylvania researchers.
Two authors pose a new theory about lowering the cost of care: Make medical school more affordable. A new editorial up at the New England Journal of Medicine, suggests we may be in (or approaching) a medical education bubble market. As patients expect more affordable care and medical school tuition rises, that bubble could be […]
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
A case study in the New England Journal of Medicine shows the results of the world’s first thought-controlled bionic leg–a prosthetic leg that moves when the wearer thinks about it moving. The U.S. Army’s Telemedicine and Advanced Technology Research Center funded the study, which took place at the Rehabilitation Institute of Chicago, to the tune […]